Further trials of a drug which could some day treat celiac disease have been approved and will begin later this year. Trials will be carried out in two-parts (single and repeated) in 32 patients at a world-leading site for celiac disease research in Finland. The study will be a double-blind, placebo-controlled, dose escalation study of the drug, currently named BL-7010
The primary objective of the study is to assess the safety of single and repeated ascending doses of the drug in well-controlled celiac patients.
So, what exactly is this drug and how does it hope to treat celiac disease?
BL-7010 has a high affinity for gliadins, the proteins in gluten which cause celiac disease. By segregating these proteins, the drug effectively masks them from enzymatic degradation and prevents the formation of peptides which trigger the immune system. The drug is eventually excreted with gliadin from the digestive tract, preventing the absorption of these peptides into the blood. This significantly reduces the immune response triggered by gluten.
“We are very enthusiastic about this unique product, which is generating a lot of excitement from both the scientific and medical communities. Despite the unmet medical need and the huge size of the celiac market, there is no available treatment for the disease apart from a lifelong gluten-free diet, which is extremely difficult to maintain. Since there are also very few products currently in clinical-stage development, we see a significant opportunity in this market for our product.” – Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx (the biopharmaceutical development company developing the drug).
We look forward to hearing more about this trial and it’s findings!
Post authored by Laura (Gluten Free Traveller) http://glutenfreetraveller.com/